There is a need for new systemic sclerosis subset criteria. A content analytic approach.
ABSTRACT
Objectives. Systemic sclerosis (SSc) is heterogeneous. The objectives of this study were to evaluate the purpose, strengths and limitations of existing SSc subset criteria, and identify ideas among experts about subsets.
Methods. We conducted semi-structured interviews with randomly sampled international SSc experts. The interview transcripts underwent an iterative process with text deconstructed to single thought units until a saturated conceptual framework with coding was achieved and respondent occurrence tabulated. Serial cross-referential analyses of clusters were developed.
Results. Thirty experts from 13 countries were included; 67% were male, 63%
were from Europe and 37% from North America; median experience of 22.5 years, with a median of 55 new SSc patients annually. Three thematic clusters regarding subsetting were identified: research and communication; management;
and prognosis (prediction of internal organ involvement, survival). The strength of the limited/diffuse system was its ease of use, however 10% stated this system had marginal value. Shortcomings of the diffuse/limited classification were the risk of misclassification, predictions/generalizations did not always hold true, and that the elbow or knee threshold was arbitrary. Eighty-seven percent use more than 2 subsets including: SSc sine scleroderma, overlap conditions, antibodydetermined subsets, speed of progression, and age of onset (juvenile, elderly).
Conclusions.
We have synthesized an international view of the construct of SSc subsets in the modern era. We found a number of factors underlying the construct of SSc subsets. Considerations for the next phase include rate of change and hierarchal clustering (e.g. limited/diffuse, then by antibodies). used to identify patients with differential disease evolution, response to therapy, and prognosis. (7, 11, 19, 20) In a new era of earlier identification of disease (21) (22) (23) , autoantibody profiling(24, 25), genetic markers (26) , biomarkers (27) and personalized medicine (22) , the construct of 'subsets in SSc' may have evolved.
Development of new subset criteria for SSc is being undertaken, led by the international steering committee of American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) classification criteria for
SSc. An important first step is to evaluate the current construct underpinning the meaning and utility of SSc subset criteria. It is also important to understand the strengths and limitations of previous iterations of SSc subset criteria so that a new iteration of SSc subset criteria will build upon the strengths and address the limitations.
The aim of this study is to evaluate the construct of SSc subsets in the modern era. Specifically, the objectives of this study are to evaluate the meaning and purpose of SSc subset criteria; determine the strengths and limitations of existing SSc subset criteria, and identify potential areas for improvement. An accurate understanding of the construct underlying SSc subsets will inform the study design of the new iteration of SSc subset classification criteria development. 
Methods

RESULTS
SSc experts. Thirty experts from 13 countries were successfully recruited. The participants were predominantly male (67%), European (63%) and practiced adult rheumatology (87%) with a median of 22.5 (interquartile range 17.3) years in practice seeing SSc patients. Two investigators were involved in previous SSc subset classification criteria development. Table 1 summarizes participant characteristics.
Meaning of SSc subsets. The term SSc subsets meant 'distinguish patients'
into 'distinct groups' using terms 'differentiate', 'stratify', 'separate', 'divide' and Strengths of Limited/Diffuse classification system. 100% of experts endorsed using the limited/diffuse cutaneous subset system. Experts stated the strengths of the limited/diffuse subset system are its 'ease of use' and 'simple to understand.' It 'has prognostic value,' 'informs what to look for,' 'useful for management' and 'applicable for research.' However, 10% of experts stated that this system has little or no value. One expert stated, 'I put it in the note to communicate to other physicians . I have more tools and am more comprehensive in how we evaluate patient.' Another expert stated 'I hate these criteria, the skin is the wrong thing.'
The shortcomings of the limited cutaneous and diffuse cutaneous SSc system grouped into 4 thematic clusters. Under thematic cluster "Misclassification" experts expressed concern relating to the observation that 'all diffuse starts as are not always true. This system is 'not good enough for predicting organ involvement,' and 'doesn't work for lung.' A third thematic cluster related to the use of the elbow as a cutaneous threshold as participants felt that it is an 'absolute breakdown without context,' is 'arbitrary,' and that the 'forearm are diffuse in action. A fourth thematic cluster related to dependence on the skin for classification. Participants expressed the 2 subset system 'does not account for progression or regression,' does not reflect the intermediate subtype, and 'only includes observed skin thickening. Participants opined that 'in early disease the skin is not the major organ,' and 'skin alone is not useful.' Other comments included 'limited is not well defined,' 'the system does not capture disease severity or disease activity,' 'is missing antibodies,' does not account 'for rate of physiologic change,' and is an 'oversimplification.' Number and types of subsets. Eighty-seven percent of experts use more than 2 SSc subsets. In practice, the participants endorsed using 2 to 10 subsets. Our results provide important considerations for the next phase of criteria development. Experts continue to be influenced by the degree of skin involvement. Skin involvement is a manifestation that is relatively easy to measure, is low cost and can be ascertained in any setting. However, an emerging concept not included in previous iterations of SSc subset criteria is the rate of skin change. Methods of assessing rate of skin change have been proposed. (33) (34) (35) The next iteration of subset criteria should consider the feasibility of incorporating rate of change and its predictive validity for informing response to therapy, internal organ involvement and survival. The time from disease onset may also affect cutaneous subsetting, and will need to be accounted for. One may argue that there may not be 1 subset classification system that serves all purposes. Subclassification will create more homogeneous groups, but the groups may need to be different based on the intended purpose (to understand pathophysiology, prevention or prognosis). The question then, is which is needed most by clinicians? Our findings suggest the international expert community prefers subset criteria to be associated with future outcomes, namely response to therapy and prognosis. For example, experts in this study stated it would be 'helpful to identify patients who have a poor prognosis' and 'warrant more aggressive therapy', thereby conferring more personalized medicine. Ideally subset criteria would help facilitate giving the right drug to the right patient. Once subsets are identified, it is important to evaluate predictors of trajectory, and then ascertain if these predictors can guide treatment. However, it should be remembered that subset classification based on pathophysiology and prognosis may not be stable over time as future outcomes can change.
Strengths of this study include interview of a large number of SSc experts, and 
